Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: Wright Reports
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aegerion Pharmaceuticals Inc Reaffirms FY 2013 Revenue Guidance

Tuesday, 30 Apr 2013 07:00am EDT 

Aegerion Pharmaceuticals Inc reaffirmed fiscal 2013 guidance and expects global net revenues of $15 million to $25 million for fiscal 2013 with 250 to 300 patients on JUXTAPID therapy globally by year-end 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $24.5 million for fiscal 2013. 

Company Quote

1.6 +4.88%
12:32pm EDT